138 results on '"Messchendorp, A Lianne"'
Search Results
2. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: A nested case-control study
3. Th1-dominant cytokine responses in kidney patients after COVID-19 vaccination are associated with poor humoral responses
4. Systemic oxidative stress may be associated with reduced IgG antibody titers against SARS-CoV-2 in vaccinated kidney transplant recipients: A post-hoc analysis of the RECOVAC-IR observational study
5. The role of interleukin-21 in COVID-19 vaccine–induced B cell–mediated immune responses in patients with kidney disease and kidney transplant recipients
6. Adherence to preventive measures after SARS-CoV-2 vaccination and after awareness of antibody response in kidney transplant recipients in the Netherlands: a nationwide questionnaire study
7. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial
8. The effect of COVID-19 vaccination on kidney function and HLA antibody formation in patients with end-stage kidney disease and on kidney replacement treatment
9. SARS-CoV-2 Spike-specific IFN-γ T-cell Response After COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
10. Predictors of Nonseroconversion to SARS-CoV-2 Vaccination in Kidney Transplant Recipients
11. Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients
12. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease:A nested case-control study
13. The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
14. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease
15. The role of interleukin-21 in COVID-19 vaccine–induced B cell–mediated immune responses in patients with kidney disease and kidney transplant recipients
16. Adherence to preventive measures after SARS-CoV-2 vaccination and after awareness of antibody response in kidney transplant recipients in the Netherlands: a nationwide questionnaire study
17. Vaccinated kidney transplant recipients are yet not sufficiently protected against COVID-19
18. The Role of Interleukin-21 in COVID-19 Vaccine-Induced B Cell-Mediated Immune Responses in Kidney Disease Patients and Kidney Transplant Recipients
19. T1 vs. T2 weighted magnetic resonance imaging to assess total kidney volume in patients with autosomal dominant polycystic kidney disease
20. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial
21. Adherence to preventive measures after SARS-CoV-2 vaccination and after awareness of antibody response in kidney transplant recipients in the Netherlands:a nationwide questionnaire study
22. The role of interleukin-21 in COVID-19 vaccine–induced B cell–mediated immune responses in patients with kidney disease and kidney transplant recipients
23. Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy
24. Estimation of Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
25. Kidney Transplant Recipients Become Less Adherent to Preventive Measures after SARS‑CoV‑2 Vaccination and after Awareness of Antibody Response
26. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease
27. Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients
28. Th1-dominant cytokine responses in kidney patients after COVID-19 vaccination are associated with poor humoral responses.
29. Blockade of HMGB1 Attenuates Diabetic Nephropathy in Mice
30. Severe Rhabdomyolysis After COVID-19 Vaccine
31. COVID-19 Vaccination Response in Kidney Transplant Recipients With and Without Mycophenolate Mofetil: Follow-up of a Randomized Controlled Trial
32. COVID-19 Vaccination Response in Kidney Transplant Recipients With and Without Mycophenolate Mofetil:Follow-up of a Randomized Controlled Trial
33. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease:Consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
34. The RECOVAC Immune-response Study:The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
35. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
36. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
37. Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant.
38. Alternative Strategies to Increase the Immunogenicity of Covid-19 Vaccines in Kidney Transplant Recipients Not Responding to Two or Three Doses of an mRNA Vaccine. A Randomized Clinical Trial
39. Antibody and T-Cell Responses 6 Months after Covid-19 mRNA-1273 Vaccination in Patients with Chronic Kidney Disease, on Dialysis, or Living with a Kidney Transplant
40. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
41. The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant
42. ADPKD:Risk Prediction for Treatment Selection
43. The RECOVAC IR study:the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant
44. update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
45. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
46. ADPKD: Risk Prediction for Treatment Selection
47. The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
48. Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD
49. Somatostatin in renal physiology and autosomal dominant polycystic kidney disease
50. Renal functional reserve capacity before and after living kidney donation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.